Clinical Trial: A Phase 1 Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar(R) (sorafenib) in Healthy Volunteers

U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797427) titled 'A Phase 1 Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar(R) (sorafenib) in Healthy Volunteers' on Jan. 22.

Brief Summary: The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar(R) in healthy volunteers.

Study Start Date: Feb. 10

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: DPH001

100 mg

DRUG: Nexavar (Sorafenib)

200 mg

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Disruptive Pharma

Disclaimer: Curated by HT Syndication....